DDInter518 DDInter1628
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Metamfetamine
Metamfetamine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) resembles {v} (Compound) Cinacalcet
Cinacalcet {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) binds {v} (Gene) HTR2C
HTR2C {u} (Gene) covaries with {v} (Gene) DNAJB2
DNAJB2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) resembles {v} (Compound) Cinacalcet
Cinacalcet {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) regulates {v} (Gene) ACOT9
ACOT9 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) binds {v} (Gene) HTR2C
HTR2C {u} (Gene) regulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) interacts with {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) upregulates {v} (Gene) ARL4C
ARL4C {u} (Gene) regulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) upregulates {v} (Gene) CHN1
CHN1 {u} (Gene) regulates {v} (Gene) PSMG1
PSMG1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Dexfenfluramine {u} (Compound) upregulates {v} (Gene) ARL4C
ARL4C {u} (Gene) is regulated by {v} (Gene) ZNF263
ZNF263 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dexfenfluramine may lead to a major life threatening interaction when taken with Metamfetamine and Metamfetamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Dexfenfluramine (Compound) resembles Cinacalcet (Compound) and Cinacalcet (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Dexfenfluramine (Compound) binds HTR2C (Gene) and HTR2C (Gene) covaries with DNAJB2 (Gene) and DNAJB2 (Gene) is downregulated by Ruxolitinib (Compound)
Dexfenfluramine (Compound) resembles Cinacalcet (Compound) and Cinacalcet (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Dexfenfluramine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) regulates ACOT9 (Gene) and ACOT9 (Gene) is downregulated by Ruxolitinib (Compound)
Dexfenfluramine (Compound) binds HTR2C (Gene) and HTR2C (Gene) regulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Dexfenfluramine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) interacts with MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Dexfenfluramine (Compound) upregulates ARL4C (Gene) and ARL4C (Gene) regulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Dexfenfluramine (Compound) upregulates CHN1 (Gene) and CHN1 (Gene) regulates PSMG1 (Gene) and PSMG1 (Gene) is downregulated by Ruxolitinib (Compound)
Dexfenfluramine (Compound) upregulates ARL4C (Gene) and ARL4C (Gene) is regulated by ZNF263 (Gene) and ZNF263 (Gene) is upregulated by Ruxolitinib (Compound)